Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- CheckyesterdayChange DetectedThe study page now returns a 403 Forbidden error, replacing the previously visible trial details with an access-denied message. This blocks access to core information about the trial, including its status, eligibility, locations, and contacts.SummaryDifference20%

- Check8 days agoChange DetectedThe page revision has been upgraded from v3.6.6 to v3.7.0, indicating a new version of the page. This update likely includes minor adjustments to layout or content without changing the core study information.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing Revision: v3.6.5, indicating a minor version update to the page’s template or underlying platform.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page revision was updated to v3.6.5, signaling a minor update to the page. This change represents a backend or UI update rather than a modification to study details.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a small backend/UI update that does not affect the study details or displayed information.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, indicating a small maintenance update to the page's documentation or rendering.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.